(Q73276261)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Immunomodulatory effects of interferon beta-1a in multiple sclerosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Z Liu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Cotleur

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J C Lee

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R A Rudick

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuroimmunology

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1-2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

153-162

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Immunologic therapy of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

The immunobiology of multiple sclerosis: an autoimmune disease of the central nervous system

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Autoreactivity to myelin antigens: myelin/oligodendrocyte glycoprotein is a prevalent autoantigen

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Cytokine profile of myelin basic protein-reactive T cells in multiple sclerosis and healthy individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Therapeutic strategies in multiple sclerosis. I. Immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Identification of an epitope derived from human proteolipid protein that can induce autoreactive CD8+ cytotoxic T lymphocytes restricted by HLA-A3: evidence for cross-reactivity with an environmental microorganism

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

IFN-beta differentially regulates CD40-induced cytokine secretion by human dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

The role of IL-10 in crossregulation of TH1 and TH2 responses

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Cellular responses to interferons and other cytokines: the JAK-STAT paradigm

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Recombinant Interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Suppression by IL-10 and IL-4 of cytokine production induced by two-way autologous mixed lymphocyte reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Interleukin (IL)-10 inhibits nuclear factor kappa B (NF kappa B) activation in human monocytes. IL-10 and IL-4 suppress cytokine synthesis by different mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Cytokine secretion of myelin basic protein reactive T cells in patients with multiple sclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

Interferon-beta inhibits progression of relapsing-remitting experimental autoimmune encephalomyelitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0165-5728%2800%2900403-3

7 January 2021

10.1016/S0165-5728(00)00403-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11108944%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference